Rosiglitazone maleate

Ferroptosis|||PPAR|||TRP/TRPV Channel|||Autophagy

-20

Rosiglitazone maleate (BRL 49653) is the maleate salt of rosiglitazone, an orally-active thiazolidinedione with antidiabetic properties and potential antineoplastic activity.

Rosiglitazone maleate is the maleic acid salt form of rosiglitazone, a potent insulin sensitizer, which is used for the treatment of diabetes. Rosiglitazone belongs to a group of compounds, thiazolidinediones (TZDs), which selectively ligate the nuclear transcription factor peroxisome-proliferator-activated receptor-gamma (PPARgamma). As a TZD, rosiglitazone improves the sensitivity of end organs to insulin through PPARgamma activation which poteniates them to lower concentrations of blood glucose. Despite of its beneficial effects of targeting insulin resistance, recent studies has shown that rosiglitazone is associated with several moderate to severe adverse effects, including hemodilution, anemia, weight gain, and edema as well as increased risk for heart failure and myocardial ischemic events.